GLAMIN amino acids/dipeptides 250mL intravenous infusion injection bottle Australia - engleză - Department of Health (Therapeutic Goods Administration)

glamin amino acids/dipeptides 250ml intravenous infusion injection bottle

fresenius kabi australia pty ltd - glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); histidine, quantity: 6.8 g/l; alanine, quantity: 16 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g; equivalent: glycine, qty 10.27 g); glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glutamine, qty 20 g; equivalent: glycine, qty 10.27 g); glutamic acid, quantity: 5.6 g/l; phenylalanine, quantity: 5.85 g/l; valine, quantity: 7.3 g/l; leucine, quantity: 7.9 g/l; tryptophan, quantity: 1.9 g/l; methionine, quantity: 5.6 g/l; isoleucine, quantity: 5.6 g/l; serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; arginine, quantity: 11.3 g/l; threonine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l - injection, intravenous infusion - excipient ingredients: citric acid; water for injections - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

SMOFKABIVEN LOW OSMO amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion 2500 mL biofine bag Australia - engleză - Department of Health (Therapeutic Goods Administration)

smofkabiven low osmo amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion 2500 ml biofine bag

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium oleate; sodium hydroxide; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN LOW OSMO amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion1950 mL biofine bag Australia - engleză - Department of Health (Therapeutic Goods Administration)

smofkabiven low osmo amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion1950 ml biofine bag

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium oleate; sodium hydroxide; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN LOW OSMO amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion 1400 mL biofine bag Australia - engleză - Department of Health (Therapeutic Goods Administration)

smofkabiven low osmo amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion 1400 ml biofine bag

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium oleate; sodium hydroxide; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN LOW OSMO amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion 850 mL biofine bag Australia - engleză - Department of Health (Therapeutic Goods Administration)

smofkabiven low osmo amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion 850 ml biofine bag

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium oleate; sodium hydroxide; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

HYDROCODONE BITARTRATE AND ACETAMINOPHEN tablet Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

hydrocodone bitartrate and acetaminophen tablet

redpharm drug, inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7) - acetaminophen 325 mg - hydrocodone bitartrate and acetaminophen tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings], reserve hydrocodone bitartrate and acetaminophen tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): • have not been tolerated, or are not expected to be tolerated, • have not provided adequate analgesia, or are not expected to provide adequate analgesia hydrocodone bitartrate and acetaminophen tablets are contraindicated in patients with: • significant respiratory depression [see warnings] • acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings] • known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings] • hypersensitiv

HYDROCODONE BITARTRATE AND ACETAMINOPHEN tablet Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

hydrocodone bitartrate and acetaminophen tablet

sun pharmaceutical industries, inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7) - acetaminophen 325 mg - hydrocodone bitartrate and acetaminophen tablets, usp are indicated for the management of moderate to moderately severe pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve hydrocodone bitartrate and acetaminophen tablets, usp for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): hydrocodone bitartrate and acetaminophen tablets, usp are contraindicated in patients with:

ACETAMINOPHEN tablet Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

acetaminophen tablet

mckesson packaging services business unit of mckesson corporation - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - acetaminophen 325 mg - acetaminophen 325mg....................analgesic/antipyretic temporary relief of minor aches and pains associated with - common cold - headache - toothache - muscular aches - backache - arthritis - menstrual cramps - and reduction of fever analgesic/antipyretic

AMINOPHYLLINE injection solution Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

aminophylline injection solution

american regent laboratories, inc. - aminophylline (unii: 27y3kjk423) (aminophylline - unii:27y3kjk423) - 25 mg in 1 ml

acetaminophen, caffeine and dihydrocodeine bitartrate- Acetaminophen, Caffeine and Dihydrocodeine Bitartrate tablet Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

acetaminophen, caffeine and dihydrocodeine bitartrate- acetaminophen, caffeine and dihydrocodeine bitartrate tablet

mikart, inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (codeine - unii:q830pw7520) - tablet - 712.8 mg - acetaminophen, caffeine and dihydrocodeine bitartrate tablets are indicated for the relief of moderate to moderately severe pain. this combination product is contraindicated in patients with hypersensitivity to dihydrocodeine, codeine, acetaminophen, caffeine, or any of the inactive components listed above, or in any situation where opioids are contraindicated including significant respiratory depression (in unmonitored settings or in the absence of resuscitative equipment), acute or severe bronchial asthma or hypercapnia, and paralytic ileus. this combination product is subject to the provisions of the controlled substance act, and has been placed in schedule iii. dihydrocodeine can produce drug dependence of the codeine type and therefore has the potential of being abused. like other opioid analgesics, dihydrocodeine may produce subjective effects other than analgesia (e.g., euphoria, relaxation), which may contribute to abuse by some patients. psychological dependence, physical dependence, and tolerance ma